Literature DB >> 27599161

Stage 4S neuroblastoma tumors show a characteristic DNA methylation portrait.

Anneleen Decock1,2, Maté Ongenaert1, Bram De Wilde1,2,3, Bénédicte Brichard4, Rosa Noguera5, Frank Speleman1,2, Jo Vandesompele1,2,6.   

Abstract

Stage 4S neuroblastoma (NB) is a special type of NB found in infants with metastases at diagnosis and is associated with an excellent outcome due to its remarkable capacity to undergo spontaneous regression. As genomics have not been able to explain this intriguing clinical presentation, we here aimed at profiling the DNA methylome of stage 4S NB to better understand this phenomenon. To this purpose, differential methylation analyses between International Neuroblastoma Staging System (INSS) stage 4S, stage 4 and stage 1/2 were performed, using methyl-CpG-binding domain (MBD) sequencing data of 14 stage 4S, 14 stage 4, and 13 stage 1/2 primary NB tumors (all MYCN non-amplified in order not to confound results). Stage 4S-specific hyper- and hypomethylated promoters were determined and further characterized for genomic localization and function by cytogenetic band enrichment, gene set enrichment, transcription factor target enrichment and differential RNA expression analyses. We show that specific chromosomal locations are enriched for stage 4S differentially methylated promoters and that stage 4S tumors show characteristic hypermethylation of specific subtelomeric promoters. Furthermore, genes involved in important oncogenic pathways, in neural crest development and differentiation, and in epigenetic processes are differentially methylated and expressed in stage 4S tumors. Based on these findings, we describe new biological mechanisms possibly contributing to the stage 4S-specific tumor biology and spontaneous regression. In conclusion, this study is the first to describe the highly characteristic stage 4S DNA methylome. These findings will open new avenues to further unravel the NB pathology in general and stage 4S disease specifically.

Entities:  

Keywords:  DNA methylation; methyl-CpG-binding domain (MBD) sequencing; neuroblastoma; spontaneous regression; stage 4S (MS)

Year:  2016        PMID: 27599161      PMCID: PMC5094630          DOI: 10.1080/15592294.2016.1226739

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  50 in total

1.  A novel significance score for gene selection and ranking.

Authors:  Yufei Xiao; Tzu-Hung Hsiao; Uthra Suresh; Hung-I Harry Chen; Xiaowu Wu; Steven E Wolf; Yidong Chen
Journal:  Bioinformatics       Date:  2012-02-09       Impact factor: 6.937

2.  DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights.

Authors:  Soledad Gómez; Giancarlo Castellano; Gemma Mayol; Mariona Suñol; Ana Queiros; Marina Bibikova; Kristopher L Nazor; Jeanne F Loring; Isadora Lemos; Eva Rodríguez; Carmen de Torres; Jaume Mora; José I Martín-Subero; Cinzia Lavarino
Journal:  Epigenomics       Date:  2015-06-12       Impact factor: 4.778

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance.

Authors:  Marta M Alonso; Juan Fueyo; Jerry W Shay; Kenneth D Aldape; Hong Jiang; Ok-Hee Lee; David G Johnson; Jing Xu; Yasuko Kondo; Takao Kanzawa; Satoru Kyo; B Nebiyou Bekele; Xian Zhou; Janice Nigro; J Matthew McDonald; W K Alfred Yung; Candelaria Gomez-Manzano
Journal:  J Natl Cancer Inst       Date:  2005-11-02       Impact factor: 13.506

5.  Functional and physical interactions between mammalian achaete-scute homolog 1 and myocyte enhancer factor 2A.

Authors:  Z Mao; B Nadal-Ginard
Journal:  J Biol Chem       Date:  1996-06-14       Impact factor: 5.157

6.  Correlating telomerase activity levels with human neuroblastoma outcomes.

Authors:  E Hiyama; K Hiyama; T Yokoyama; Y Matsuura; M A Piatyszek; J W Shay
Journal:  Nat Med       Date:  1995-03       Impact factor: 53.440

7.  PAG-3, a Zn-finger transcription factor, determines neuroblast fate in C. elegans.

Authors:  Scott Cameron; Scott G Clark; Joan B McDermott; Eric Aamodt; H Robert Horvitz
Journal:  Development       Date:  2002-04       Impact factor: 6.868

8.  Over-expression of AhR (aryl hydrocarbon receptor) induces neural differentiation of Neuro2a cells: neurotoxicology study.

Authors:  Eiichi Akahoshi; Seiko Yoshimura; Mitsuko Ishihara-Sugano
Journal:  Environ Health       Date:  2006-09-07       Impact factor: 5.984

9.  WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013.

Authors:  Jing Wang; Dexter Duncan; Zhiao Shi; Bing Zhang
Journal:  Nucleic Acids Res       Date:  2013-05-23       Impact factor: 16.971

10.  Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.

Authors:  Anneleen Decock; Maté Ongenaert; Robrecht Cannoodt; Kimberly Verniers; Bram De Wilde; Geneviève Laureys; Nadine Van Roy; Ana P Berbegall; Julie Bienertova-Vasku; Nick Bown; Nathalie Clément; Valérie Combaret; Michelle Haber; Claire Hoyoux; Jayne Murray; Rosa Noguera; Gaelle Pierron; Gudrun Schleiermacher; Johannes H Schulte; Ray L Stallings; Deborah A Tweddle; Katleen De Preter; Frank Speleman; Jo Vandesompele
Journal:  Oncotarget       Date:  2016-01-12
View more
  9 in total

Review 1.  The roles played by the MYCN, Trk, and ALK genes in neuroblastoma and neural development.

Authors:  Mayumi Higashi; Kohei Sakai; Shigehisa Fumino; Shigeyoshi Aoi; Taizo Furukawa; Tatsuro Tajiri
Journal:  Surg Today       Date:  2019-03-08       Impact factor: 2.549

2.  Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531.

Authors:  Clare J Twist; Arlene Naranjo; Mary Lou Schmidt; Sheena C Tenney; Susan L Cohn; Holly J Meany; Peter Mattei; E Stanton Adkins; Hiroyuki Shimada; Wendy B London; Julie R Park; Katherine K Matthay; John M Maris
Journal:  J Clin Oncol       Date:  2018-11-16       Impact factor: 44.544

Review 3.  Neuroblastoma, a Paradigm for Big Data Science in Pediatric Oncology.

Authors:  Brittany M Salazar; Emily A Balczewski; Choong Yong Ung; Shizhen Zhu
Journal:  Int J Mol Sci       Date:  2016-12-27       Impact factor: 5.923

Review 4.  11q deletion in neuroblastoma: a review of biological and clinical implications.

Authors:  Vid Mlakar; Simona Jurkovic Mlakar; Gonzalo Lopez; John M Maris; Marc Ansari; Fabienne Gumy-Pause
Journal:  Mol Cancer       Date:  2017-06-29       Impact factor: 27.401

5.  Monozygotic twins with neuroblastoma MS have a similar molecular profile: a case of twin-to-twin metastasis.

Authors:  Margaret Shatara; Ana C Xavier; Alan Dombkowski; Daniela Cukovic; Janet M Poulik; Deniz Altinok; Yubin Ge; Jeffrey W Taub
Journal:  Br J Cancer       Date:  2019-10-11       Impact factor: 7.640

Review 6.  Neuroblastoma and the epigenome.

Authors:  Irfete S Fetahu; Sabine Taschner-Mandl
Journal:  Cancer Metastasis Rev       Date:  2021-01-06       Impact factor: 9.264

7.  5-Methylcytosine and 5-Hydroxymethylcytosine Signatures Underlying Pediatric Cancers.

Authors:  Shalu Jhanwar; Ajinkya Deogade
Journal:  Epigenomes       Date:  2019-05-09

8.  Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program.

Authors:  Carlos Jiménez; Roberta Antonelli; Mariona Nadal-Ribelles; Laura Devis-Jauregui; Pablo Latorre; Carme Solé; Marc Masanas; Adrià Molero-Valenzuela; Aroa Soriano; Josep Sánchez de Toledo; David Llobet-Navas; Josep Roma; Francesc Posas; Eulàlia de Nadal; Soledad Gallego; Lucas Moreno; Miguel F Segura
Journal:  Mol Cancer       Date:  2022-09-03       Impact factor: 41.444

Review 9.  Methylation of DNA and chromatin as a mechanism of oncogenesis and therapeutic target in neuroblastoma.

Authors:  Ram Mohan Ram Kumar; Nina Felice Schor
Journal:  Oncotarget       Date:  2018-04-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.